Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Holding BNTX?
Track your performance easily
BNTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$76.53 - $131.49
Previous Close$110.64
Volume1.24M
Average Volume (3M)988.33K
Market Cap
$26.30B
Enterprise Value$9.32B
Total Cash (Recent Filing)$16.55B
Total Debt (Recent Filing)$219.10M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Mar 10, 2025EPS Estimate
$0.71Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding237,725,735
10 Day Avg. Volume808,756
30 Day Avg. Volume988,325
Standard Deviation0.23
R-Squared0.00333
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)1.30
Price to Sales (P/S)6.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit2.89
Enterprise Value/Ebitda3.95
Forecast
1Y Price Target
$138.62Price Target Upside25.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
BioNTech SE News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBioNTech 3Q24 revenues of ~€1.2B beat consensus of €406.6M, and our estimate of €638.5M, due to earlier approval for COVID-19 vaccines in the US, a positive.
Oncology AdvancementsThe novel immuno-oncology asset BNT327 in clinical development could significantly enhance BNTX's standing in the oncology market.
Research And DevelopmentOver 90% of the company's current R&D spending is on non-COVID-19-related activities, indicating a strong focus on diversifying its research efforts.
Bears Say
Financial PerformanceBioNTech recorded a net loss per diluted share of €3.36 per share—meaningfully worse than the previous forecast for net earnings of €1.16 per share.
Product Development And Market EntryBioNTech and Pfizer's combo influenza-COVID-19 vaccine only met one of the two primary immunogenicity objectives in a Phase 3 trial.
Regulatory And Clinical TrialsBioNTech announced an FDA partial clinical hold on the Ph 3 trial of gotistobart in anti-PD1 relapsed / refractory non-small cell lung cancer.
---
Ownership Overview
― Insiders
3.31% Mutual Funds
7.48% Other Institutional Investors
88.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
Currently, no data Available
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2025 which is in 120 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 04, 2024. The company reported $0.881 earnings per share for the quarter, beating the consensus estimate of -$1.669 by $2.55.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.53 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is $0.71.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,766,240 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $0.881 in its last earnings report, beating expectations of -$1.669. Following the earnings report the stock price went down -2.252%.
Which hedge fund is a major shareholder of BioNTech SE?
Among the largest hedge funds holding BioNTech SE’s share is PRIMECAP Management Co. It holds BioNTech SE’s shares valued at 385M.
---
BioNTech SE Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$138.62 (25.29% Upside)
$138.62 (25.29% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 38.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $161.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.06%
12-Months-Change
Fundamentals
Return on Equity
-2.37%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
BNTX Company Deck
---
BNTX Earnings Call
Q3 2024
0:00 / 0:00
---
BNTX Stock 12 Month Forecast
Average Price Target
$138.62
▲(25.29% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+24.12%
reiterated a buy rating 7 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.12% per trade.
---